Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-102 Phase 1 in Healthy and Obese Adults
NCT06309667Phase 1Completed
- Sponsor
- PROGEN
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PG-102 in obesity and Overweight (11 cohorts), sponsored by PROGEN. Primary endpoints: Treatment-emergent adverse events at Day 57, Serious adverse events at Day 57 and 2 more. Started Mar 2024; status: completed.
02
Drugs
PG-102
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06309667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309667.